Financial Outlook

In 2026, the company expects continued growth in its biological and dermatology portfolio, led by key products like Ebglyss, Illumetri, Wynzora, and Klisyri. R&D will focus on early-stage innovation, advancing six proof-of-concept studies and further developing Ebglyss. Almmirall will also pursue strategic acquisitions while maintaining a prudent financial approach.